Analyst Price Target is $50.33
▼ -22.06% Downside Potential
This price target is based on 11 analysts offering 12 month price targets for Alpine Immune Sciences in the last 3 months. The average price target is $50.33, with a high forecast of $65.00 and a low forecast of $18.00. The average price target represents a -22.06% upside from the last price of $64.58.
Current Consensus is
Hold
The current consensus among 11 contributing investment analysts is to hold stock in Alpine Immune Sciences. This Hold consensus rating has held steady for over two years.
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.
Read More
